glp 1 agonists and sglt2 inhibitors combination Updated evidence on cardiovascular renal effects of GLP-1 receptor and therapy with and finerenone: a narrative review and perspectives | Cardiovascular Diabetology Metabolic Powerhouses: GLP-1 RAs and
Description
King A, Miller EM
The positive results from these trials ultimately led to the approval of Ozempic for clinical use
It has a higher molecular weight (4,813 versus 4,114 Daltons)
They were assigned 10 or 15 mg of tirzepatide or placebo for 52 weeks
Some evidence suggests allulose may improve insulin sensitivity and reduce postprandial glucose spikes, independent of GLP-1 activation
